Morbidity and Mortality Outcomes of Dupilumab for Cutaneous Immune-Related Adverse Events

JAMA Oncology 2026 Open access

Read full text
Authors: Brandon Block, Jaanvi Mehta, Shayan Owji, Dan Feng, T. Marron, Nicholas Gulati
DOI: 10.1001/jamaoncol.2025.6092
Cited by: 7
References: 5

Abstract

This cohort study evaluates morbidity and mortality outcomes associated with dupilumab treatment in patients with cutaneous immune-related adverse events.

Fields of Study & Subjects

Dermatology and Skin Diseases Psoriasis: Treatment and Pathogenesis Hidradenitis Suppurativa and Treatments

Publication details

Journal / source
JAMA Oncology
Publisher
American Medical Association (AMA)
Volume
12
Issue
3
Pages
321–321
Publication date
22 January 2026
Language
EN